Company Encyclopedia
View More
name
Sinocare
300298.SZ
Sinocare Inc. engages in the development, manufacture, and marketing of rapid diagnosis testing products primarily in the People’s Republic of China. It offers blood glucose and pressure monitors; point of care testing products; digital management tool solutions; non-invasive screening products; and PTS and Trividia products. The company provides its products for the patients with chronic diseases and diabetes, as well as for healthcare professionals.
890.25 B
300298.SZMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking11/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.68%B
    • Profit Margin5.98%B
    • Gross Margin43.06%B
  • Growth ScoreB
    • Revenue YoY12.10%B
    • Net Profit YoY27.17%B
    • Total Assets YoY5.31%B
    • Net Assets YoY2.78%C
  • Cash ScoreB
    • Cash Flow Margin1672.04%B
    • OCF YoY12.10%B
  • Operating ScoreB
    • Turnover0.77B
  • Debt ScoreC
    • Gearing Ratio41.19%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sinocare has repurchased 1.22% of its shares, costing 139 million yuan

    According to the Zhitong Finance APP, Sinocare announced that as of October 31, 2025, the company has repurchased a total of 6.8275 million shares through centralized bidding, accounting for 1.22% of the company's current total share capital, with a total transaction amount of 139 million yuan (excluding transaction fees)

    Zhitong·
    SZ
    300298
    +0.06%
    Zhitong·
    SZ
    300298
    +0.06%

    Hebei Broadcasting Wireless Media Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Hebei Broadcasting Wireless Media Co., Ltd. reported its earnings for the nine months ending September 30, 2025. Sales decreased to CNY 447.96 million from CNY 458.03 million year-over-year. However, net income increased to CNY 217.08 million from CNY 189.01 million. Basic and diluted earnings per share from continuing operations rose to CNY 0.5427, up from CNY 0.525 in the previous year.

    marketscreener·
    SZ
    301551
    +1.47%
    marketscreener·
    SZ
    301551
    +1.47%

    Sinocare released its performance for the first three quarters, with a net profit attributable to the parent company of 211 million yuan, a decrease of 17.36%

    According to the Zhitong Finance APP, Sinocare released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 3.453 billion yuan, a year-on-year increase of 8.52%. The net profit attributable to shareholders of the listed company was 211 million yuan, a year-on-year decrease of 17.36%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 180 million yuan, a year-on-year decrease of 22.13%. The basic earnings per share were 0.3827 yuan

    Zhitong·
    SZ
    300298
    +0.06%
    Zhitong·
    SZ
    300298
    +0.06%

    00:22 ET Sinocare presenta sus soluciones integrales para el manejo de la diabetes en EASD

    Sinocare showcased its comprehensive diabetes management solutions at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) in Vienna. The company organized an international symposium highlighting the clinical performance of its iCan CGM system, featuring expert presentations on its effectiveness in adult and pediatric populations. Sinocare also launched the iCan i6 CGM, emphasizing its user-friendly design and global accessibility. Additionally, the company introduced its "A+C" Diabetes Prevention and Control Ecosystem, integrating non-invasive detection with continuous glucose monitoring for improved patient care.

    prnewswire·
    SZ
    300298
    +0.06%
    prnewswire·
    SZ
    300298
    +0.06%

    09:33 ET Sinocare präsentiert seine umfassenden Lösungen für das Diabetesmanagement auf der EASD

    Sinocare showcased its comprehensive diabetes management solutions at the successful 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) in Vienna. The company hosted an international symposium highlighting the clinical performance of its iCan CGM system, with presentations from experts on its effectiveness and usability. Sinocare also introduced the next-generation iCan i6 CGM system, featuring enhanced user experience and global accessibility. Additionally, the company presented its new diabetes prevention ecosystem, integrating non-invasive screening with CGM for early risk detection and intervention.

    prnewswire·
    SZ
    300298
    +0.06%
    prnewswire·
    SZ
    300298
    +0.06%
    © 2025 Longbridge｜Disclaimer